← board
INMB
Inmune Bio, Inc.distress 5/10 · elevated risk$1.76-4%today-44% from 52w high
Neurology 1Oncology 1
Lead: recessive dystrophic epidermolysis bullosa (RDEB)
Revenue
pre-revenue
Liquidity
$21M
Runway
1.1 yrs
Shares 1y
0%
Price & events
+3.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.3%
1D
-15.0%
1W
+23.9%
1M
+27.5%
3M
+3.5%
6M
-38.5%
1Y
-79.2%
2Y
-91.6%
5Y
-90.0%
All
Overview
- Market Cap
- $46.79M
- Enterprise Value
- $40.43M
- Volume
- 113.23K
- 52 Week Range
- $1.12 – $3.16
- Total Shares
- 26.59M
- Float Shares
- 22.13M
- Short %
- 12.99%
- % Held by Insiders
- 11.23%
- % Held by Institutions
- 19.68%
- RVOL
- 0.10x
- Beta
- 0.98
Pipeline stages · 2 programs
INKmune
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XPro1595
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-10 | Phase 1/2 | INKmune | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 12 | completed |
| 2025-05-12 | Phase 2 | XPro1595fast track | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment | 208 | completed |
Catalyst news & presentations · 25
- 2027Guided 40%trial initiationsecondaryPhase 3XPro · Phase 3 initiationSEC 8-K
- 2026Guided 40%readoutPhase 2XPro1595 · Additional MRI analyses from MINDFuL trial expected.SEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3CORDStrom (Ebstrocel) · Confirmatory Phase 3 trial expected to open in 2026.SEC 8-K
- Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)CORDStrom · EU and U.S. regulatory submissions to followSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- July 12–15, 2026Confirmed 100%conferencedata presentationsecondaryPhase 2XPro1595 · Complete chi-separation dataset presentation at AAIC 2026.SEC 8-K
- mid-summer 2026regulatory submissionFiled (NDA/BLA)CORDStrom · Planned MAA submission to MHRASEC 8-K
- mid-summer 2026regulatory submissionFiled (NDA/BLA)CORDStrom · Targeted filing of full Marketing Authorization Application (MAA) to UK MHRASEC 8-K
- 2026-06-23fda agreementCORDStrom (Ebstrocel) · MHRA pre-MAA meeting minutes confirm agreement across CMC, non-clinical, and clinical evidence packages; recognizes MissionEB Phase 2 data as clinically meaningful.SEC 8-K
- 2026-04-29partnershipCORDStrom · Amended and restated Material Transfer and License Agreement with Anthony Nolan for umbilical cord tissue supply.SEC 8-K
- February 27, 2026 at 9:30 a.m. ETconferencedata presentationsecondaryPhase 3XPro1595 · Webinar detailing registrational strategy and Phase 2 MINDFuL resultsSEC 8-K
- February 26, 2026 at 1:00 p.m. ETconferencedata presentationsecondaryPhase 3CORDStrom · Webinar presenting new clinical data from MissionEB Phase III trial.SEC 8-K
- 2026-02-12fda agreementCORDStrom · Received official minutes from End-of-Phase 2 (Type B) meeting with FDASEC 8-K
- February 10, 2026regulatory submissionFiled (NDA/BLA)CORDStrom · Submitted pre-submission package to UK MHRASEC 8-K
- December 2025regulatory submissionFiled (NDA/BLA)CORDStrom · US BLA submissionSEC 8-K
- Q4readoutCORDStrom · CORDStrom RDEB trial data anticipated from independent statistical analysisSEC 8-K
- December 4, 2025, 7:15am - 5:00pm PTconferencedata presentationsecondaryValidation of Early Mild Alzheimer's Cognitive Composite (EMACC) through associations with blood-based biomarkersSEC 8-K
- December 1-4, 2025conferencedata presentationsecondaryPhase 2XPro1595 · Present new neuroimaging data from Phase 2 MINDFuL trial at CTAD conference.SEC 8-K
- 2025-08-07partnershipCORDStrom · Partnered with Cell and Gene Therapy Catapult for large-scale manufacturingSEC 8-K
- 4PM ET on Thursday, July 31, 2025conferencedata presentationsecondaryPhase 2XPro · Video detailing additional MINDFuL trial findings published on YouTube.SEC 8-K
- June 2025readoutPhase 2XPro · Top-line cognition results (EMACC)SEC 8-K
- 1H25conferencedata presentationsecondaryINKmune · NK Priming Platform Data at NK SummitSEC 8-K
- March 4, 2025conferencedata presentationsecondaryPhase 1INKmune · Phase I data presentation at Innate Killer SummitSEC 8-K
- 2025-02-06partnershipCORDStrom · Licensed MissionEB clinical trial data from Great Ormond Street Hospital for CORDStrom in RDEBSEC 8-K
- year-end 2024trial initiationsecondaryPhase 2XPro · Phase 2 trial opensSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+298% upside) · 4 analysts
- 2026-03-11LUCID CAPITAL MARKETSNeutral → Buy
- 2025-07-02Maxim GroupBuy
- 2025-07-01BTIGBuy → Neutral
- 2025-07-01ScotiabankSector Outperform → Sector Underperform
- 2025-02-13Maxim GroupBuy
- 2025-02-11ScotiabankSector Outperform
Competitors — recessive dystrophic epidermolysis bullosa (RDEB)
- none identified
Recent news
- 2026-07-22Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
- 2026-07-21INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
- 2026-07-20INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
- 2026-07-20INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
- 2026-07-20INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan
- 2026-07-20INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - Yahoo Finance
- 2026-07-20INmune Bio reports press release available - Bitget
- 2026-07-17INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.